-+ 0.00%
-+ 0.00%
-+ 0.00%

BeyondSpring publishes corporate presentation on plinabulin immune-modulating cancer therapy pipeline

PUBT·04/22/2026 22:07:02
Listen to the news
BeyondSpring publishes corporate presentation on plinabulin immune-modulating cancer therapy pipeline
  • BeyondSpring investor deck highlighted plinabulin as lead late-stage asset, positioning it as a first-in-class, reversible tubulin depolymerizing agent with immune-modulating activity.
  • DUBLIN-3 Phase 3 trial in 2L/3L NSCLC EGFR wild type reported overall survival benefit for plinabulin + docetaxel vs docetaxel, with OS HR 0.82.
  • Study showed median OS 10.5 months for plinabulin + docetaxel vs 9.4 months for docetaxel.
  • Safety readout cited grade 4 neutropenia reduction on day 8 across all cycles, with 22.3% on plinabulin + docetaxel vs 43.5% on docetaxel.
  • Pipeline update flagged SEED targeted protein degradation platform, with lead oral RBM39 degrader entering Phase 1.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.